LGR4/GPR48 recombinant proteins and antibodies

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), also called GPR48, is a G protein-coupled receptor (GPCR) that is primarily expressed in various tissues, including the intestines, liver, breast, and prostate. LGR4 plays a significant role in cell proliferation, differentiation, migration, and the maintenance of tissue homeostasis, particularly during developmental processes. It acts as a key regulator of the Wnt/β-catenin signaling pathway, interacting with Wnt ligands to activate downstream cellular signaling. As a result, LGR4 plays a critical role in processes such as tumorigenesis, immune response, and tissue repair.

Studies have shown that LGR4 is abnormally expressed in several cancers, particularly in colorectal cancer, breast cancer, prostate cancer, and lung cancer. Overexpression of LGR4 can promote tumor cell proliferation, invasion, and metastasis, while potentially influencing immune responses within the tumor microenvironment. Additionally, LGR4 is involved in regulating inflammatory responses and immune tolerance, suggesting potential therapeutic applications in autoimmune and inflammatory diseases.

Currently, drug development targeting LGR4 is in its early stages, with research focused on small molecule inhibitors, antibody therapies, and other biological agents that modulate LGR4 function. Small molecule inhibitors work by blocking the interaction between LGR4 and Wnt ligands, thereby inhibiting its activation and reducing tumor cell proliferation and metastasis. Anti-LGR4 monoclonal antibodies specifically target the LGR4 receptor, suppressing its function and modulating immune responses. LGR4-targeted therapies hold promise for providing new treatment options for cancer, inflammatory diseases, and autoimmune conditions. As understanding of LGR4’s function deepens, LGR4-targeted drugs are expected to become important tools for cancer immunotherapy and the treatment of other immune-related diseases in the coming years.

To assist in the development of LGR4 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for LGR4 targets. Products include active LGR4 recombinant proteins, full-length LGR4 proteins, LGR4 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of LGR4 biotherapy, DIMA BIOTECH has also prepared a LGR4 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple LGR4 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.